FGP
BIO icon

Freestone Grove Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Freestone Grove Partners’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41.1M Buy
147,605
+37,081
+34% +$10.7M 0.29% 119
2025
Q4 		$33.5M Buy
+110,524
New +$34.5M 0.24% 130
2025
Q3 		– Sell
-73,616
Closed -$17.8M – 715
2025
Q2 		$17.8M Buy
+73,616
New +$17.4M 0.13% 213
2025
Q1 		– Sell
-46,015
Closed -$15.1M – 596
2024
Q4 		$15.1M Buy
+46,015
New +$15.6M 0.19% 164

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Freestone Grove Partners's BIO Position: Q1 2026 in Review

Freestone Grove Partners increased its Bio-Rad Laboratories Class A (BIO) stake by 34% in Q1 2026, buying an estimated $10.7M and bringing the position to 147,605 shares worth $41.1M. The position accounts for 0.29% of the portfolio, ranked #119.

Freestone Grove Partners first reported a position in BIO in Q4 2024 and has held it in 4 quarters since. 391 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

  • Freestone Grove Partners held 147,605 shares of Bio-Rad Laboratories Class A worth $41.1M as of Q1 2026.
  • Freestone Grove Partners bought 37,081 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $10.7M.
  • Bio-Rad Laboratories Class A made up 0.29% of Freestone Grove Partners's portfolio in Q1 2026, its #119 holding.
  • Freestone Grove Partners first reported a position in Bio-Rad Laboratories Class A in Q4 2024 and has held it in 4 quarters since.
  • 391 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.